<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This Schedule contains summary financial information extracted from (a) the
Balance Sheet and Statement of Operations filed as part of the Quarterly Report
on Form 10-Q and is qualified in its entirety by reference to such (b) Report on
Form 10-Q.
</LEGEND>
<CIK>                         0000792641
<NAME>                        Bio-Reference Laboratories, Inc.

<S>                                              <C>
<PERIOD-TYPE>                                    9-MOS
<FISCAL-YEAR-END>                                           OCT-31-2000
<PERIOD-END>                                                JUL-31-2000
<CASH>                                                        1,056,162
<SECURITIES>                                                          0
<RECEIVABLES>                                                22,218,261
<ALLOWANCES>                                                 22,789,956
<INVENTORY>                                                     650,290
<CURRENT-ASSETS>                                             24,403,167
<PP&E>                                                        5,578,768
<DEPRECIATION>                                                3,720,224
<TOTAL-ASSETS>                                               36,897,854
<CURRENT-LIABILITIES>                                        21,988,677
<BONDS>                                                      15,915,079
                                                 0
                                                      60,408
<COMMON>                                                         81,405
<OTHER-SE>                                                   24,358,045
<TOTAL-LIABILITY-AND-EQUITY>                                 36,897,854
<SALES>                                                      48,487,299
<TOTAL-REVENUES>                                             48,487,299
<CGS>                                                        27,073,690
<TOTAL-COSTS>                                                47,533,919
<OTHER-EXPENSES>                                              1,126,300
<LOSS-PROVISION>                                              6,494,240
<INTEREST-EXPENSE>                                            1,184,060
<INCOME-PRETAX>                                               (172,920)
<INCOME-TAX>                                                          0
<INCOME-CONTINUING>                                           (172,920)
<DISCONTINUED>                                                        0
<EXTRAORDINARY>                                                       0
<CHANGES>                                                             0
<NET-INCOME>                                                  (172,920)
<EPS-BASIC>                                                       (.02)
<EPS-DILUTED>                                                     (.02)


</TABLE>



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission